Introduction
============

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the second leading cause of cancer mortality globally.[@b1-ott-10-3843] Hepatic resection and orthotopic liver transplantation is still the most effective treatment for HCC. However, the efficacy of current therapeutic regimens is poor due to the high frequency of recurrence and metastasis of HCC.[@b2-ott-10-3843],[@b3-ott-10-3843] Therefore, the identification of specific and sensitive biomarkers for the recurrence and prognosis of HCC is urgently needed.

miRNAs are crucially implicated in a diverse range of human diseases, including cancer.[@b4-ott-10-3843],[@b5-ott-10-3843] Accumulating evidence indicates that dysregulation of miRNAs, especially within natural carriers and exosomes, contributes to the onset and progression of various human tumors such as breast and liver cancer.[@b6-ott-10-3843]--[@b9-ott-10-3843] Exosomes are small membrane vesicles (40--120 nm) which play key roles in intercellular communication via delivery of active biological molecules.[@b10-ott-10-3843],[@b11-ott-10-3843] Extracellular miRNAs in exosomes are relatively stable and shielded against extracellular RNase degradation.[@b12-ott-10-3843]--[@b14-ott-10-3843] Therefore, exosomal miRNAs may serve as noninvasive biomarkers for the diagnosis and prognosis of various malignancies.[@b8-ott-10-3843],[@b12-ott-10-3843],[@b15-ott-10-3843]

Previous studies reported that miR-125b was downregulated in HCC tissue, and plasma miR-125b may be a diagnostic marker for HCC.[@b5-ott-10-3843],[@b16-ott-10-3843]--[@b20-ott-10-3843] However, the potential significance of circulating exosomal miR-125b in HCC has not been explored. In this study, we aimed to determine whether the detection of exosomal miR-125b in HCC patients will provide information for predicting the recurrence and prognosis of HCC.

Materials and methods
=====================

Patients and samples
--------------------

Clinical samples were collected from two independent cohorts of patients recruited from Zhongshan Hospital, Fudan University (Shanghai, China) between January and June 2012. Cohort 1 comprised 30 patients with HCC, 30 with chronic hepatitis B (CHB), and 30 with liver cirrhosis (LC); cohort 2 comprised 128 patients with HCC. HCC patients in both cohorts had undergone curative resection and were histologically diagnosed. Clinical samples were collected from all participants after obtaining informed consent. This study and the informed consent was approved by Ethics Committee of Zhongshan Hospital, Fudan University. The clinical characteristics of all participants were shown in [Table 1](#t1-ott-10-3843){ref-type="table"}. None of the HCC patients had received any preoperative treatment. Patients were followed every 3 months for the first year, and then every 6 months until June 22, 2016. The follow-up included serum AFP level detection, abdominal ultrasonography, and chest X-ray. When recurrence was suspected, enhanced computed tomography (CT) scanning or enhanced magnetic resonance imaging (MRI) was performed. Time to recurrence (TTR) was defined as the interval between surgery and the detected recurrence. Overall survival (OS) was calculated as the time from surgery to death or the last observation point.

Blood samples were collected and centrifuged at 3,000 rpm for 10 min to separate serum. Exosomes were isolated from serum samples and treated with ExoQuick Exosome Precipitation Solution (System Biosciences, Palo Alto, CA, USA) according to the manufacturer's protocol. The exosome samples were stored at −80°C for later analysis.

Electron microscopy and nanoparticle tracking analysis (NTA)
------------------------------------------------------------

The morphology of exosomes was examined by transmission electron microscopy (TEM) as described previously.[@b21-ott-10-3843] Briefly, exosomes were fixed in 1% glutaraldehyde, and then loaded onto formvar/carbon coated copper grids. The samples were negatively stained with 1% uranyl acetate and examined under a Tesla BS242 transmission electron microscope (Tescan, Brno, Czech Republic) operated at 80 kV. The exosomes were analyzed using NanoSight LM10 system (NanoSight, Malvern, Worcestershire, UK) equipped with fast video capture and NTA (NanoSight).

Western blot analysis
---------------------

RIPA buffer was used to lyse the exosome pellet and BCA method was performed to determine protein concentration. An amount of 20 µg of protein fraction was run on 10% SDS-PAGE and transferred to nitrocellulose membranes and blocked in tris-buffered saline containing 5% non-fat dry milk and 0.1% tween-20 (TBST) for 1 h. The membranes were incubated with CD9, CD63 or GAPDH antibody (Sigma-Aldrich Co., St Louis, MO, USA) at 4°C overnight. The membranes were washed three times with TBST and incubated with HRP-conjugated secondary antibodies (Santa Cruz Biotechnology Inc., Dallas, TX, USA) for 1 h at room temperature. The bands were visualized using a Clarity™ Western ECL Substrate Kit (Bio-Rad Laboratories Inc., Hercules, CA, USA) and analyzed with an LAS-4000 Luminescent Image Analyzer (Fujifilm, Tokyo, Japan).

Quantitative real-time polymerase chain reaction (qRT-PCR)
----------------------------------------------------------

Total RNA was extracted from the exosomes, whole serum, and exosome-depleted supernatants using MirVana™ miRNA Isolation Kit (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA). TaqMan probe for miR-125b (Applied Biosystems, Thermo Fisher Scientific) was used for qRT-PCR. TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Thermo Fisher Scientific) was used to synthesize cDNA, and amplification was performed by TaqMan Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems, Thermo Fisher Scientific). ABI PRISM 7900 Sequence Detection System (Applied Biosystems, Thermo Fisher Scientific) was used to analyze miR-125b relative expression normalized to *Caenorhabditis elegans* miRNA (*Cel*-miR-39) (Applied Biosystems, Thermo Fisher Scientific) as previously described.[@b22-ott-10-3843],[@b23-ott-10-3843]

Statistical analysis
--------------------

Statistical analysis was performed using SPSS for Windows version 16.0. Categorical data were analyzed by *χ*^2^ or Fisher's exact test. OS and TTR were calculated by the Kaplan--Meier method and the differences were analyzed by the log-rank test. Univariate and multivariate analyses were performed using the Cox proportional hazards regression model. The accuracy of predicting prognosis was evaluated by the ROC curves, and predicting performance was investigated by the area under the ROC curve (AUC). ROC and regression analysis was performed with MedCalc software (version 10.4.7.0; MedCalc, Mariakerke, Belgium). *P*\<0.05 was considered statistically significant.

Results
=======

Identification of the isolated serum exosomes
---------------------------------------------

To characterize the isolated serum exosomes, first we detected the expression of CD63 and CD9 in the exosomes isolated from HCC patients ([Figure 1A](#f1-ott-10-3843){ref-type="fig"}). Western blot analysis showed that exosomal markers CD63 and CD9 were both enriched in the isolated exosome pellets. Next, we employed TEM and NTA to identify the shape and size of the exosomes. TEM revealed that exosomes had a spherical shape and a size of 32.38--70.88 nm (determined from 20 exosomes) ([Figure 1B](#f1-ott-10-3843){ref-type="fig"}). NTA assay demonstrated that exosomes had a characteristic size of 53.6±12.3 nm and a concentration of 1.16×10^9^ particles/mL (n=3) ([Figure 1C](#f1-ott-10-3843){ref-type="fig"}). These results indicated that the collected exosomes had been purified adequately.

Differential expression profile of miR-125b
-------------------------------------------

qRT-PCR was performed to detect miR-125b levels in the exosomes, the whole serum, and exosome-depleted supernatants from the participants. As shown in [Figure 2A](#f2-ott-10-3843){ref-type="fig"}, miR-125b levels in exosomes were significantly increased compared with that in the whole serum or exosome-depleted supernatant (*P*\<0.01, respectively) in patients of cohort 1, including CHB (n=30), LC (n=30), and HCC (n=30). Furthermore, serum miR-125b levels were remarkably decreased in HCC group compared with CHB and LC groups (*P*\<0.01, respectively). Interestingly, exosomal miR-125b level in HCC group was inferior to that in CHB (*P*\<0.01) and LC patients (*P*=0.06), but only the difference with CHB group was statistically significant (*P*\<0.01). The difference of miR-125b levels in exosome-depleted supernatant among HCC, CHB, and LC groups was not statistically significant. Therefore, miR-125b levels in exosomes and whole serum were validated in HCC patients of cohort 2. The results demonstrated that miR-125b level in whole serum was significantly decreased compared with that in exosomes (*P*\<0.01, respectively) both in HCC patients of cohort 1 (n=30) and 2 (n=128), but the difference in miR-125b level in whole serum or exosomes between the two cohorts was not statistically significant (*P*\>0.05, respectively, [Figure 2B](#f2-ott-10-3843){ref-type="fig"}).

Association of miR-125b levels with clinicopathological features of HCC patients
--------------------------------------------------------------------------------

The median follow-up for cohort 2 (128 HCC patients) was 29.1 months (range 2.9--52.4 months). OS rate at 3 years after operation was 75.8%. To further explore whether miR-125b levels in serum and exosomes could be associated with clinicopathological parameters of HCC, 128 patients of cohort 2 were divided into two groups based on the median level of miR-125b expression. As shown in [Table 2](#t2-ott-10-3843){ref-type="table"}, low expression of miR-125b in serum was significantly correlated with tumor encapsulation (*P*=0.047), and low expression of miR-125b in exosomes was significantly correlated with tumor number, differentiation, and TNM stage (*P*\<0.01, *P*\<0.01, and *P*=0.011, respectively). Furthermore, the Kaplan--Meier curves for TTR and OS were plotted according to the levels of exosomal and serum miR-125b ([Figure 3](#f3-ott-10-3843){ref-type="fig"}). The patients with low levels of exosomal miR-125b had shorter TTR and OS than those with high levels of miR-125b (*P*\<0.01, respectively). However, the patients with low serum miR-125b levels had poorer TTR than those with high levels (*P*\<0.01). Additionally, univariate and multivariate analysis revealed that microvascular invasion (MVI) and miR-125b levels in exosomes, but not serum miR-125b levels, were independent prognostic factors for TTR and OS in patients with HCC (*P*\<0.01, respectively) ([Table 3](#t3-ott-10-3843){ref-type="table"}).

ROC and regression analysis
---------------------------

To further explore whether MVI or exosomal miR-125b level could be used as potential predictive prognostic markers of HCC, we used ROC curves to analyze the sensitivity, specificity, and AUC value of MVI and exosomal miR-125b level ([Figure 4](#f4-ott-10-3843){ref-type="fig"}). The results demonstrated that exosomal miR-125b level showed high accuracy in predicting the recurrence (AUC =0.739) and survival (AUC =0.702) in HCC patients after liver resection. A combination of exosomal miR-125b and MVI had better power of discrimination, with an AUC of 0.807 (recurrence) and 0.765 (survival) (*P*\<0.05, respectively) ([Table 4](#t4-ott-10-3843){ref-type="table"}).

Discussion
==========

Despite recent progress in the diagnosis and treatment of HCC, the prognostic outcome of HCC patients is still poor due to the high frequency of recurrence and metastasis after surgery.[@b2-ott-10-3843],[@b3-ott-10-3843] In this study, our results showed that serum exosomal miR-125b was an independent predictive factor associated with TTR and OS in HCC patients, thus offering timely and comprehensive treatment alternatives. Therefore, we speculated that exosomal miR-125b is an important prognostic marker to improve the efficacy of current treatment regimens and the survival of HCC patients.

Exosomes are small membrane vesicles secreted by various types of cells.[@b10-ott-10-3843],[@b11-ott-10-3843] Exosomes play pivotal roles in inter-cellular communication via delivery of biological cargoes, including proteins, mRNAs, and miRNAs.[@b10-ott-10-3843] Recently, miRNAs in exosomes have been investigated as valuable biomarkers of malignancy. First, exosomes can specifically reflect their original cell types and conditions, and they may harbor circulating biomarkers of particular accuracy, even at early stages of cancer which are difficult or impossible to detect.[@b24-ott-10-3843],[@b25-ott-10-3843] Second, miRNAs are enriched and relatively stable in exosomes due to the protection of the lipid bilayer and shelter against extracellular RNase degradation.[@b14-ott-10-3843] In the present study, we measured miR-125b levels in the whole serum, exosome-depleted supernatant, and exosomes in patients with CHB, LC, and HCC. Our results demonstrated that exosomal miR-125b levels were significantly increased compared with miR-125b levels in the serum or exosome-depleted supernatant in all patients. These findings indicate that miR-125b in the exosome is more enriched compared with that in circulating serum.

Dysregulated miRNAs and their target genes are involved in HCC initiation and progression.[@b26-ott-10-3843],[@b27-ott-10-3843] miR-125b has been reported as a tumor suppressor for HCC and could suppress epithelial-mesenchymal transition, tumor growth, migration, and invasion of hepatoma cells by directly regulating oncogenes such as *SMAD2/4*, *Sirtuin7*, *SUV39H1*, *LIN28B*, and *PIGF*.[@b16-ott-10-3843],[@b17-ott-10-3843],[@b28-ott-10-3843]--[@b30-ott-10-3843] However, the expression pattern of circulating exosomal miR-125b and its clinicopathological significance in HCC remain unknown. Our present study revealed that exosomal miR-125b expression in HCC patients was significantly downregulated compared to CHB patients, consistent with previously reported results.[@b18-ott-10-3843],[@b31-ott-10-3843] Furthermore, our results showed that the lower expression of exosomal miR-125b was associated with tumor number, differentiation, and TNM stage of HCC. These clinicopathologic features represent a more aggressive HCC subtype. In addition, HCC patients with lower exosomal miR-125b levels had shorter TTR and OS than those with high levels of miR-125b, indicating that miR-125b in exosomes may suppress HCC growth, migration, and invasion.[@b32-ott-10-3843]

Previous studies have reported that plasma miR-125b levels were downregulated in HCC patients and could be used as diagnostic marker for hepatitis B virus-induced HCC.[@b18-ott-10-3843],[@b31-ott-10-3843] In agreement with these results, we found that serum levels of miR-125b in patients with HCC were remarkably down-regulated compared to those with CHB and LC. Although low serum level of miR-125b was significantly correlated with tumor encapsulation, it was not an independent prognostic factor for TTR and OS in patients with HCC, which was consistent with the previous study.[@b33-ott-10-3843] miR-125b in circulating serum, compared with miR-125b in exosomes, may function through a different mechanism in HCC.

There are several limitations to our study. First, our sample size is small and long-term follow-up is required to confirm the relationship between exosomal miR-125b levels and patient outcome. A retrospective study with a large cohort should be considered to confirm the clinical significance of our findings. Second, the study did not include healthy participants. HCC often arises in patients with several risk factors, such as aflatoxin exposure, alcohol abuse, chronic HBV or HCV infection, and LC. However, it has been shown that HCC rarely develops in healthy people without these risks.[@b34-ott-10-3843] Third, the potential mechanisms of exosomal miR-125b in HCC were not elucidated.

In conclusion, our findings suggest that exosomal miR-125b may serve as a novel serological biomarker with significant accuracy in predicting postoperative recurrence and survival of HCC patients. Exosomal miR-125b may help discriminate HCC patients with high risk of recurrence and poor prognosis, and guide timely comprehensive therapy for these patients.
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![Characterization of exosomes isolated from the serum of HCC patients.\
**Notes:** (**A**) Western blot analysis of the expression of proteins enriched in exosomes, including CD63 and CD9. As the control, GAPDH was not detected in exosomes. (**B**) Transmission electron microscopy analysis of the morphology of exosomes (scale bar: 200 nm). (**C**) Nanoparticle tracking analysis to quantify the size and concentration of exosomes.\
**Abbreviation:** HCC, hepatocellular carcinoma.](ott-10-3843Fig1){#f1-ott-10-3843}

![The relative expression of miR-125b in the subjects.\
**Notes:** (**A**) qRT-PCR was performed to measure miR-125b levels in exosomes, the whole serum, and exosome-depleted supernatant from patients of cohort 1, including CHB (n=30), LC (n=30), and HCC (n=30). (**B**) miR-125b relative expression in exosomes and the whole serum was detected in HCC patients of cohort 1 (n=30) and 2 (n=128). \*\* *P*\<0.01.\
**Abbreviations:** qRT-PCR, quantitative real-time polymerase chain reaction; CHB, chronic hepatitis B; LC, liver cirrhosis; HCC, hepatocellular carcinoma; NS, not significant.](ott-10-3843Fig2){#f2-ott-10-3843}

![Kaplan--Meier analysis of cumulative recurrence and overall survival in HCC patients.\
**Notes:** After operation (n=128; cohort 2) according to miR-125b expression in exosomes (**A** and **B**) and serum (**C** and **D**). *P*-values were calculated by the log-rank test and *P*\<0.05 denoted significance.\
**Abbreviation:** HCC, hepatocellular carcinoma.](ott-10-3843Fig3){#f3-ott-10-3843}

![ROC curve analysis for MVI and exosomal miR-125b in HCC patients (n=128; cohort 2).\
**Notes:** ROC curves for predicting the recurrence of MVI (**A**), exosomal miR-125b (**B**), and combination of exosomal miR-125b and MVI (**C**). ROC curves for predicting the survival of MVI (**D**), exosomal miR-125b (**E**), and combination of exosomal miR-125b and MVI (**F**).\
**Abbreviations:** MVI, microvascular invasion; HCC, hepatocellular carcinoma; AUC, area under the ROC curve.](ott-10-3843Fig4){#f4-ott-10-3843}

###### 

Clinical characteristics of the participants

  Variables                                                           Cohort 1      Cohort 2                  
  ------------------------------------------------------------------- ------------- ------------ ------------ -------------
  Gender                                                                                                      
   Male                                                               27 (90.0%)    27 (90.0%)   27 (90.0%)   110 (85.9%)
   Female                                                             3 (10.0%)     3 (10.0%)    3 (10.0%)    18 (14.1%)
  Age, years                                                                                                  
   ≥50                                                                21 (70.0%)    20 (66.7%)   22 (73.3%)   98 (76.6%)
   \<50                                                               9 (30.0%)     10 (33.3%)   8 (26.7%)    30 (23.4%)
  HBsAg                                                                                                       
   Positive                                                           30 (100.0%)   27 (90.0%)   28 (93.3%)   121 (94.5%)
   Negative                                                           0 (0.0%)      3 (10.0%)    2 (6.7%)     7 (5.5%)
  GGT, U/L                                                                                                    
   ≥54                                                                10 (33.3%)    8 (26.7%)    12 (40.0%)   58 (45.3%)
   \<54                                                               20 (66.7%)    22 (73.3%)   18 (60.0%)   70 (54.7%)
  AFP, ng/mL                                                                                                  
   ≥20                                                                                           18 (60.0%)   77 (60.2%)
   \<20                                                                                          12 (40.0%)   51 (39.8%)
  LC                                                                                                          
   No                                                                                            9 (30.0%)    31 (24.2%)
   Yes                                                                                           21 (70.0%)   97 (75.8%)
  Tumor size, cm                                                                                              
   ≥5                                                                                            14 (46.7%)   55 (43.0%)
   \<5                                                                                           16 (53.3%)   73 (57.0%)
  Tumor number                                                                                                
   Single                                                                                        24 (80.0%)   97 (75.8%)
   Multiple                                                                                      6 (20.0%)    31 (24.2%)
  MVI                                                                                                         
   No                                                                                            16 (53.3%)   65 (50.8%)
   Yes                                                                                           14 (46.7%)   63 (49.2%)
  Tumor encapsulation                                                                                         
   Complete                                                                                      12 (40.0%)   51 (39.8%)
   None                                                                                          18 (60.0%)   77 (60.2%)
  Tumor differentiation[\#](#tfn1-ott-10-3843){ref-type="table-fn"}                                           
   I+II                                                                                          16 (53.3%)   75 (58.6%)
   III+IV                                                                                        14 (46.7%)   53 (41.4%)
  TNM stage                                                                                                   
   I                                                                                             9 (30.0%)    48 (37.5%)
   II+III                                                                                        21 (70.0%)   80 (62.5%)

**Notes:**

Tumor differentiation was assigned using the Edmondson's grading system. The data is formatted as n (%).

**Abbreviations:** AFP, alpha-fetoprotein; CHB, chronic hepatitis B; GGT, gamma-glutamyl transferase; HCC, hepatocellular carcinoma; LC, liver cirrhosis; MVI, microvascular invasion; TNM, tumor-node-metastasis.

###### 

Correlation between miR-125b expression and clinical characteristics of HCC (cohort 2, n=128)

  Clinical characteristics                                            n     Serum miR-125b   *P*-value   Exosomal miR-125b                                  *P*-value        
  ------------------------------------------------------------------- ----- ---------------- ----------- -------------------------------------------------- ----------- ---- --------------------------------------------------
  Gender                                                                                                                                                                     
   Male                                                               110   52               58          0.13                                               53          57   0.31
   Female                                                             18    12               6                                                              11          7    
  Age, years                                                                                                                                                                 
   ≥50                                                                98    51               47          0.40                                               51          47   0.40
   \<50                                                               30    13               17                                                             13          17   
  HBsAg                                                                                                                                                                      
   Positive                                                           121   61               60          0.70[\*](#tfn3-ott-10-3843){ref-type="table-fn"}   62          59   0.24[\*](#tfn3-ott-10-3843){ref-type="table-fn"}
   Negative                                                           7     3                4                                                              2           5    
  GGT, U/L                                                                                                                                                                   
   ≥54                                                                58    32               26          0.29                                               29          29   1.00
   \<54                                                               70    32               38                                                             35          35   
  AFP, ng/mL                                                                                                                                                                 
   ≥20                                                                77    42               35          0.21                                               42          35   0.21
   \<20                                                               51    22               29                                                             22          29   
  Cirrhosis                                                                                                                                                                  
   Yes                                                                97    53               44          0.06                                               50          47   0.54
   No                                                                 31    11               20                                                             14          17   
  Tumor size, cm                                                                                                                                                             
   ≥5                                                                 55    30               25          0.37                                               32          23   0.11
   \<5                                                                73    34               39                                                             32          41   
  Tumor number                                                                                                                                                               
   Multiple                                                           31    17               14          0.54                                               23          8    **0.002**
   Single                                                             97    47               50                                                             41          56   
  MVI                                                                                                                                                                        
   Yes                                                                63    35               28          0.22                                               35          28   0.22
   No                                                                 65    29               36                                                             29          36   
  Tumor encapsulation                                                                                                                                                        
   Complete                                                           77    33               44          **0.0477**                                         32          45   0.019
   None                                                               51    31               20                                                             32          19   
  Tumor differentiation[\#](#tfn4-ott-10-3843){ref-type="table-fn"}                                                                                                          
   III+IV                                                             53    26               27          0.86                                               36          17   **0.001**
   I+II                                                               75    38               37                                                             28          47   
  TNM stage                                                                                                                                                                  
   II+III                                                             80    41               39          0.72                                               47          33   **0.011**
   I                                                                  48    23               25                                                             17          31   
  Exosomal miR-125b                                                                                                                                                          
   High                                                               64    23               41          **0.001**                                          --          --   --
   Low                                                                64    41               23                                                             --          --   
  Serum miR-125b                                                                                                                                                             
   High                                                               64    --               --          --                                                 23          41   **0.001**
   Low                                                                64    --               --                                                             41          23   

**Notes:**

Performed by the Fisher's exact test.

Tumor differentiation was assigned using the Edmondson's grading system. The bold values indicate *P*-value \<0.05.

**Abbreviations:** AFP, alpha-fetoprotein; CHB, chronic hepatitis B; GGT, gamma-glutamyl transferase; HCC, hepatocellular carcinoma; LC, liver cirrhosis; MVI, microvascular invasion; TNM, tumor-node-metastasis.

###### 

Univariate and multivariate analysis of prognostic factors in HCC (cohort 2, n=128)

  Variables                                 TTR                  OS                               
  ----------------------------------------- -------------------- ----------- -------------------- -----------
  Univariate analysis                                                                             
   Gender, male vs female                   1.59 (0.58--4.37)    0.364       3.08 (0.71--13.8)    0.133
   Age, years, ≥50 vs \<50                  1.82 (0.80--4.16)    0.155       1.76 (0.69--4.49)    0.238
   HBsAg, positive vs negative              1.41 (0.32--6.19)    0.652       2.42 (0.65--9.02)    0.186
   GGT, U/L, ≥50 vs \<50                    1.03 (0.50--2.13)    0.935       1.42 (0.69--2.89)    0.342
   AFP, ng/mL, ≥400 vs \<400                1.74 (0.87--3.45)    0.116       1.79 (0.77--4.16)    0.176
   Cirrhosis, yes vs no                     1.11 (0.48--2.53)    0.812       1.37 (0.55--3.41)    0.500
   Tumor size, cm, ≥5 vs \<5                1.55 (0.83--2.90)    0.168       1.95 (0.95--4.03)    **0.040**
   Tumor number, multiple vs single         1.37 (0.57--3.29)    0.476       1.10 (0.45--2.73)    0.833
   MVI, yes vs no                           4.95 (2.23--11.01)   **0.000**   4.46 (1.69--11.78)   **0.003**
   Tumor encapsulation, none vs complete    1.12 (0.59--2.16)    0.726       1.14 (0.56--2.35)    0.718
   Tumor differentiation, III-IV vs I--II   1.02 (0.54--1.93)    0.958       1.60 (0.82--3.14)    0.171
   TNM stage, II+III vs I                   2.06 (0.91--4.67)    0.085       2.10 (0.88--5.02)    0.095
   Serum miR-125, high vs low               0.51 (0.25--1.05)    0.067       0.61 (0.29--1.26)    0.178
   Exosomal miR-125, high vs low            0.14 (0.06--0.33)    **0.000**   0.35 (0.16--0.77)    **0.009**
  Multivariate analysis                                                                           
   Tumor size, cm, ≥5 vs \<5                                                 1.97 (1.02--3.81)    **0.025**
   MVI, yes vs no                           3.82 (2.02--7.20)    **0.000**   4.76 (2.13--10.61)   **0.000**
   Exosomal miR-125b, high vs low           0.14 (0.07--0.29)    **0.000**   0.36 (0.18--0.74)    **0.005**

**Notes:** Cox proportional hazards regression model. The bold values indicate *P*-value \<0.05.

**Abbreviations:** AFP, alpha-fetoprotein; GGT, gamma-glutamyl transferase; HCC, hepatocellular carcinoma; MVI, microvascular invasion; OS, overall survival; TNM, tumor-node-metastasis; TTR, time to recurrence.

###### 

ROC curve analysis for predicting prognostic accuracy of recurrence in HCC patients (cohort 2; n=128)

  Variables                  AUC (95% CI)           Sensitivity   Specificity   *P*-value
  -------------------------- ---------------------- ------------- ------------- -------------------------------------------------------
  Recurrence                                                                    
   MVI                       0.716 (0.624--0.809)   0.766         0.667         **0.003**[\#](#tfn8-ott-10-3843){ref-type="table-fn"}
   Exosomal miR-125b         0.739 (0.648--0.830)   0.830         0.679         **0.048**[\#](#tfn8-ott-10-3843){ref-type="table-fn"}
   Exosomal miR-125b + MVI   0.807 (0.731--0.883)   0.787         0.716         
  Survival                                                                      
   MVI                       0.688 (0.589--0.786)   0.750         0.625         **0.032**[\#](#tfn8-ott-10-3843){ref-type="table-fn"}
   Exosomal miR-125b         0.702 (0.602--0.802)   0.825         0.534         **0.042**[\#](#tfn8-ott-10-3843){ref-type="table-fn"}
   Exosomal miR-125b + MVI   0.765 (0.682--0.848)   0.800         0.625         

**Notes:**

Compared with Exosomal miR-125b + MVI, and performed with MedCalc software. The bold values indicate *P*-value \<0.05.

**Abbreviations:** HCC, hepatocellular carcinoma; AUC, area under the ROC curve; MVI, microvascular invasion.
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